Introduction:
Prostate cancer (PC) is the second-leading cause of cancer-related death in males. It is also the most prevalent solid cancer in patients with metastatic (a condition in which cancer spreads to other body parts) prostatic cancer. Systemic therapy based on androgen deprivation continues to be the conventional initial treatment plan. However, the condition progressively worsens to castration-resistant prostate cancer despite receiving proper treatment. Prognostic tools have been created to aid in daily clinical decision-making and patient counseling in an effort to enhance prostate cancer outcomes. For patients with prostate cancer, these tools include common clinical traits and biomarkers such as alkaline phosphatase (ALP). This article summarizes that ALP has a strong predictive value for cancer outcomes in prostate cancer patients.
What Is Alkaline Phosphate?
Alkaline phosphatase (ALP) is an enzyme found in many body tissues, including the liver, bone, intestines, and placenta. It is involved in the process of removing phosphate groups from molecules such as nucleotides, proteins, and alkaloids, and it is important for many cellular processes, including bone formation and metabolism. Alkaline phosphatase is often measured as part of a routine blood test called a liver function test or a bone profile. High levels of alkaline phosphatase in the blood may be a sign of liver disease, bone disorders, or certain cancers. While low levels of alkaline phosphatase can indicate a deficiency in certain nutrients or a rare genetic disorder called hypophosphatasia.
What Is the Clinical Importance of Alkaline Phosphate?
In metastatic prostate cancer, ALP is a prognostic biomarker that indicates the course of the disease without regard to treatment. It is affordable and simple to measure tALP levels. High baseline ALP levels are linked to unfavorable outcomes in mCRPC patients, including skeletal problems and shorter survival. Furthermore, the severity of the metastatic bone disease has been linked to higher ALP levels. ALP level variations may be a reflection of variations in bone turnover and osteoblastic activity. The following are the clinical importance of alkaline phosphatase:
-
The use of baseline ALP level as a prognostic marker for overall survival in patients with metastatic prostate cancer is approved by studies.
-
The utility of changes in ALP as a marker post-therapy has yet to be completely explored.
-
ALP kinetics were prognostic for bone metastasis and death.
-
Monitoring ALP levels in mCRPC can provide prognostic information about the likely outcome of the disease.
How Is Alkaline Phosphate Used as Marker in Prostate Cancer?
ALP is largely produced by the liver and bones, with 40 to 50 percent of healthy adults. ALP levels come from bone-specific ALP (bALP). bALP is an enzyme expressed on osteoblasts' surface (bone-producing cells). The expression of the bALP enzyme resembles an osteoblastic stroma, and it helps to mineralize newly built type 1 collagen-rich bone. bALP is produced in the blood and urine as bone metastases grow. Therefore, the main component of serum total ALP (tALP) levels observed in patients with metastasis who do not have severe disease is bALP.
It has been demonstrated that ALP, a glycoprotein produced from bones, liver, kidney, or placenta, is increased and has prognostic significance for several cancers. ALP has been demonstrated to have predictive significance in prostate cancer, independently of medication. In order to improve daily oncologic clinical practice, plan follow-up, and provide advice regarding outcomes, serum ALP is a straightforward and affordable test that could serve as an objective prognostic parameter. This would facilitate the shared decision-making process with the patient.
The following are the diagnostic results for prostate cancer:
-
High baseline ALP levels have been linked to worse outcomes in prostate cancer patients, including skeletal problems and shorter life.
-
It has been demonstrated that high ALP is connected to the severity of the metastatic bone disease.
-
Studies concluded that when cancer starts to metastasize, ALP reflects bone turnover, osteoblast (a substance that makes bone) activity, and bone formation in the adjacent bone tissues.
-
ALP may indicate metastatic bone tumor (growing cell mass uncontrollably) in prostate cancer.
-
Elevated ALP has been shown in cancer patients with bone metastasis.
-
ALP could also be used as a response or monitoring marker for treatment therapies and bone-targeting therapies such as bisphosphonate.
-
Elevated bALP levels can point to either a disease condition or internal bone repair.
-
In patients with bone-dominant prostate cancer, the bALP level is employed to measure bone turnover that reflects both osteoblastic activity and the severity of the disease (the number of metastases).
-
The existence of proliferating osteoblasts is indicated by the release of bALP, which can be employed as a serum marker of elevated osteoblast activity.
-
ALP is a fast and readily available biomarker.
What Are the Disadvantages of Alkaline Phosphate?
While alkaline phosphatase (ALP) is a commonly used marker for prostate cancer, its use has some potential disadvantages. The following are the disadvantages of alkaline phosphatase:
-
Lack of Specificity: While elevated levels of ALP can be an indicator of prostate cancer, it is not a specific marker for the disease. High levels of ALP can be found in other conditions, such as liver disease, bone disorders, and even normal aging.
-
Limited Sensitivity: ALP is not always elevated in prostate cancer patients, especially in those with early-stage disease. This means that some prostate cancers may not be detected by measuring ALP levels alone.
-
Lack of Prognostic Value: ALP levels may not provide a reliable indication of the severity or aggressiveness of prostate cancer. Other markers, such as prostate-specific antigen (PSA), may be better predictors of the course of the disease.
-
Inconclusive Results: Sometimes, an increase in ALP levels may not clearly indicate prostate cancer, and further testing may be required to confirm the diagnosis.
-
Cost and Availability: Measuring ALP levels can be expensive, and not all healthcare facilities have the necessary equipment to perform the test.
Conclusion:
Alkaline phosphate may be beneficial for patient counseling as well as clinical therapy decision-making. However, the role of ALP in future aspects requires more clarification. In patients with metastatic illness to the bone, ALP is a reliable prognostic sign that needs to be regularly examined. One of the most important aspects of the clinician's interactions with patients is reassuring patients about monitoring changes. It is not advised to discontinue treatment due to changes in ALP alone; other markers of the development of the disease are required. It is necessary to carry out more studies into the function of ALP as a biomarker, including assessing the predictive significance of changes in ALP levels during therapy.
